{"id":"NCT01124045","sponsor":"Alcon Research","briefTitle":"Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery","officialTitle":"A Phase IIIB, Multicenter, Randomized, Double-Masked, Parallel-Group, Active-Controlled Study of the Safety and Efficacy of Difluprednate Ophthalmic Emulsion, 0.05% (Durezol™) 4 Times Daily (QID) and Prednisolone Acetate Ophthalmic Suspension, 1.0% (Pred Forte™) QID for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2012-04","completion":"2012-04","firstPosted":"2010-05-14","resultsPosted":"2013-06-19","lastUpdate":"2013-06-19"},"enrollment":80,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Cataracts","Inflammation"],"interventions":[{"type":"DRUG","name":"Difluprednate ophthalmic emulsion, 0.05%","otherNames":["DUREZOL™"]},{"type":"DRUG","name":"Prednisolone acetate ophthalmic suspension, 1.0%","otherNames":["PRED FORTE™"]}],"arms":[{"label":"DUREZOL","type":"EXPERIMENTAL"},{"label":"PRED FORTE","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study was to compare the safety and efficacy of Durezol™ compared to Pred Forte™ for the treatment of inflammation following cataract surgery in a pediatric population 0 to 3 years of age.","primaryOutcome":{"measure":"Percentage of Patients With an Anterior Cell Grade of 0 (no Cells) at Day 15 ± 2 Days","timeFrame":"Day 15 ± 2 days","effectByArm":[{"arm":"DUREZOL","deltaMin":78.9,"sd":null},{"arm":"PRED FORTE","deltaMin":77.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":39},"commonTop":["Cataract operation (non-study eye)","Nasopharyngitis","Ear infection","Conjunctivitis","Posterior capsule opacification"]}}